The innate myeloid immune system is a complex network of cells that protect against disease by identifying and killing pathogens and tumour cells, but it is also implicated in homoeostatic mechanisms such as tissue remodelling and wound healing. Myeloid phagocytes such as monocytes, macrophages or dendritic cells are at the basis of controlling these immune responses in all tissues of the body. In the present review, we summarize recent studies demonstrating that mTOR [mammalian (or mechanistic) target of rapamycin] regulates innate immune reactions in macrophages and dendritic cells. The mTOR pathway serves as a decision maker to control the cellular response to pathogens and tumours by regulating the expression of inflammatory mediators such as cytokines, chemokines or interferons. In addition to various in vivo mouse models, kidney transplant patients under mTOR inhibitor therapy allowed the elucidation of important innate immune functions regulated by mTOR in humans. The role of the mTOR pathway in macrophages and dendritic cells enhances our understanding of the immune system and suggests new therapeutic avenues for the regulation of pro-versus anti-inflammatory mediators with potential relevance to cancer therapy, the design of novel adjuvants and the control of distinct infectious and autoimmune diseases.
Introduction mTOR [mammalian (or mechanistic) target of rapamycin]
is an evolutionarily conserved serine/threonine kinase that senses environmental and cellular input signals to control an enormous amount of diverse processes depending on the cell type including the immune system [1] [2] [3] [4] [5] . The present review focuses on the most recent studies that have identified a role of mTOR signalling in macrophages and DCs (dendritic cells), two cardinal phagocytes of the innate immune system, to regulate immune responses and tissue homoeostasis. The function of mTOR in T-cells has been covered recently by several excellent reviews [6, 7] .
The mTOR signalling pathway mTOR is part of two known multiprotein complexes designated mTORC (mTOR complex) 1 and mTORC2
Key words: cancer, dendritic cell, immune regulation, macrophage, mammalian target of rapamycin (mTOR). Abbreviations used: cDC, conventional dendritic cell; Cot, cancer Osaka thyroid oncogene; DC, dendritic cell; 4E-BP1, eukaryotic initiation factor 4E-binding protein 1; Flt3l, Fms-like tyrosine kinase 3 ligand; FoxO1, forkhead box O1; GM-CSF, granulocyte/macrophage colonystimulating factor; IFN, interferon; IGF-1, insulin-like growth factor 1; IL, interleukin; IRF, IFN regulatory factor; LC, Langerhans cell; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; moDC, monocyte-derived DC; mTOR, mammalian (or mechanistic) target of rapamycin; mTORC, mTOR complex; NF-κB, nuclear factor κB; pDC, plasmacytoid DC; PI3K, phosphoinositide 3-kinase; PIP3, phosphatidylinositol 3,4,5-trisphosphate; raptor, regulatory associated protein of mTOR; rictor, rapamycin-insensitive companion of mTOR; STAT3, signal transducer and activator of transcription 3; TAM, tumour-associated macrophage; TGF-β, transforming growth factor β; TLR, Toll-like receptor; TNFα, tumour necrosis factor α; tpl2, tumour progression locus 2; TSC, tuberous sclerosis complex. 1 To whom correspondence should be addressed (email thomas.weichhart@ meduniwien.ac.at). [2] . Raptor (regulatory associated protein of mTOR) is the defining protein for mTORC1, whereas rictor (rapamycininsensitive companion of mTOR) and Sin1 are specific for mTORC2 [8] . The prototypical allosteric mTOR inhibitor rapamycin blocks mTORC1, whereas mTORC2 is usually insensitive to rapamycin [8] . In a previous study, a number of novel ATP-competitive mTOR inhibitors that block both mTORCs have been developed [9] . The mTOR pathway constitutes a central rheostat integrating diverse extra-and intra-cellular signals including nutrients and growth factors to control cell growth, translation and metabolism. For example, mTORC1 senses cellular energy levels by monitoring cellular ATP/AMP levels via AMPK (AMP-activated protein kinase), amino acids via Rag GTPases, signals from the Wnt family via GSK3 (glycogen synthase kinase 3) and growth factors such as insulin and IGF-1 (insulin-like growth factor 1) via the insulin receptor and the IGF-1 receptor respectively [2, 8] (Figure 1 ). mTORC2 is believed to be activated by growth factors alone [2] . Stimulation of antigen receptors, cytokine receptors [e.g. IL (interleukin)-2 receptor] or co-stimulatory receptors (e.g. CD28) promotes mTORC1 activation in T-cells [6, 7] . In macrophages and DCs, stimulation of TLRs (Tolllike receptors) by PAMPs (pathogen-associated molecular patterns) activates mTORC1 and mTORC2 [10] [11] [12] . The growth factors GM-CSF (granulocyte/macrophage colonystimulating factor) and Flt3l (Fms-like tyrosine kinase 3 ligand), which are important for DC differentiation, can also induce mTORC1 activation [13, 14] .
Activation via PI3K (phosphoinositide 3-kinase) is the best documented example of activating mTORC1 [8] . Stimulation of a growth factor receptor or TLR leads to the recruitment of PI3K to the receptor. PI3K phosphorylates PIP2 (phosphatidylinositol 4,5-bisphosphate) to generate PIP3 (phosphatidylinositol 3,4,5-trisphosphate) as a second messenger. PIP3 then recruits Akt to the plasma membrane and allows its phosphorylation and activation by PDK1 (phosphoinositide-dependent kinase 1) (Figure 1) . A main effector of Akt is TSC (tuberous sclerosis complex) 2, which is a tumour suppressor that forms a heterodimeric complex with TSC1. TSC2 is phosphorylated and inactivated by Akt, leading to a loss of suppression of mTORC1 by the TSC1-TSC2 complex [2, 8] . The active TSC1-TSC2 complex serves as a GTPase-activating protein that converts the small GTPase Rheb into its inactive GDP-bound state to prevent mTORC1 activation (Figure 1) . Inactivation of the TSC1-TSC2 complex allows the accumulation of the GTP-loaded form of Rheb, which interacts with and activates mTORC1 directly [2] . Amino-acid-induced activation of the Rag GTPases promotes the translocation of mTORC1 to lysosomal compartments that contain Rheb to allow the activation of mTORC1 via growth factors [8] . The best known mTORC1 substrates are 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) and S6K1/p70 S6K (S6 kinase), two regulators of protein synthesis.
Regulation of DC development by mTORC1
DCs provide a critical link between innate and adaptive immunity by efficiently priming pathogen-specific adaptive T-cell responses. Three subsets of DCs can be defined in the steady state in the mouse: CD8 − cDCs (conventional DCs), CD8
+ cDCs and pDCs (plasmacytoid DCs). The growth factor Flt3l controls the development of DCs from a common bone-marrow-derived DC precursor and is particularly important for the differentiation of pDCs and CD8 + cDCs [14] . Injection of recombinant Flt3l into mice induces mTORC1 activation in DCs, but not in macrophages and other cell types [14] . Inhibition of mTORC1 with rapamycin impairs Flt3l-driven DC development in vitro, with the pDCs and CD8
+ cDCs most profoundly affected. Conversely, genetic activation of the PI3K/mTOR pathway by deletion of the PI3K negative regulator PTEN (phosphatase and tensin homologue deleted on chromosome 10) facilitates Flt3l-driven DC development in vitro and in vivo [14] . LCs (Langerhans cells) are a specialized subset of DCs that populate the epidermal layer of the skin. DC-specific loss of raptor (lack of mTORC1 activity), but not of rictor (lack of mTORC2 activity), leads to a progressive decrease in LCs in the skin of mice [15] . Raptor-deficient LCs have an increased tendency to leave the skin and show increased apoptosis, suggesting that mTORC1 is critical for the preservation of the LC network in mice [15] .
Analogous results have been observed for human DC development. Here, a CD34
+ haemopoietic progenitor cell can develop into myeloid CD11c
+ DCs (homologous with mouse CD8
− cDCs), myeloid CD141 + DCs (homologous with mouse CD8 + cDCs), pDCs and LCs. Precursor proliferation and development of all of the human DC subsets requires intact PI3K/Akt/mTOR signalling [16, 17] . In contrast, the survival of terminally differentiated myeloid DCs is not dependent on PI3K or mTOR activity [16] . The differentiation of monocytes to moDCs (monocytederived DCs) by GM-CSF and IL-4 depends on mTORC1 [4, 13, 18] . Inhibition of mTOR by rapamycin during the entire moDC differentiation period induces apoptosis and generates a tolerance-promoting DC phenotype [4, 13] . However, renal transplant patients treated with the mTOR inhibitor rapamycin have similar numbers of myeloid DCs and pDCs in their blood compared with control patients [13] . These results show that mTOR inhibition at doses in the range 5-10 ng/ml, which is far beyond the concentrations used for murine studies, does not compromise the DC compartment in humans in vivo.
Regulation of inflammatory cytokines by mTOR signalling in macrophages and DCs
The co-ordinated secretion of pro-versus anti-inflammatory cytokines by monocytes, macrophages and DCs is indispensable for effective immunity and tissue homoeostasis. In a previous study, the mTOR pathway emerged as a critical regulator of the inflammatory cytokine response in innate immune cells [3] [4] [5] [6] . Stimulation of human or murine monocytes, macrophages and DCs by TLR ligands such as LPS (lipopolysaccharide) activates the mTORC1 pathway [10, 13, [19] [20] [21] [22] [23] . Inhibition of mTORC1 with rapamycin during TLR stimulation enhances the expression of the proinflammatory cytokine IL-12 via the transcription factor NF-κB (nuclear factor κB), whereas the release of the anti-inflammatory cytokine IL-10 is inhibited via reduced STAT3 (signal transducer and activator of transcription 3) activation [10] (Figure 2) . Conversely, knockdown of TSC2 results in chronic activation of mTORC1 in human monocytes and enhances IL-10, but inhibits IL-12 production via transcriptional events [10, 24] . In addition, mTORC1 promotes the expression of antiviral type I IFNs (interferons) in mDCs and pDCs, depending on the transcription factors IRF (IFN regulatory factor) 5 and IRF7 [11] . The pathogens Leishmania donovani and Listeria monocytogenes activate the mTORC1 pathway to modulate the IL-12/IL-10 balance [10, 25] . Similarly, cytokinestimulated T-cells induce IL-10 production in macrophages via PI3K and mTORC1 [26] . In line with these findings, mice with a DC-specific deletion of raptor show strongly suppressed IL-10 production in intestinal DCs and are highly susceptible to dextran sodium sulfate-induced colitis [27] . Moreover, rapamycin enhances the induction of tissue factor and the pro-inflammatory cytokine TNFα (tumour necrosis factor α) in LPS-stimulated peritoneal macrophages potentially by reducing IL-10 expression [28] . Chronic stimulation of Nod2 (nucleotide oligomerization domain 2), a bacteria-sensing intracellular protein, augments the secretion of the anti-inflammatory molecules IL-10, TGF-β (transforming growth factor β) and IL-1 receptor antagonist in a rapamycin-sensitive manner [29] . mTORC1 inhibition increases inflammation and pulmonary injury by enhancing NF-κB activity in the lung of tobacco-exposed mice and promotes the recruitment of inflammatory macrophages [30] . HIV infects macrophages and impairs innate immune signalling in part by activation of mTOR [31] . Inhibition of mTOR restores LPS-mediated TNFα expression in HIVinfected macrophages. Moreover, HIV-1 blocks autophagy by mTOR activation and impedes immune functions of DCs [32] . Therefore inhibition of mTORC1 may serve as a potential therapeutic target to up-regulate macrophage and DC innate immune responsiveness in HIV-positive persons.
In addition, it has been suggested that mTORC2 also negatively regulates pro-inflammatory cytokine production in DCs [33] . Knockdown of rictor in DCs augments the production of IL-12, TNFα and IL-8 in LPS-stimulated cells [33] . That study suggested that mTORC2-dependent phosphorylation of Akt in DCs promotes the phosphorylation and cytoplasmic retention of the transcription factor FoxO1 (forkhead box O1) resulting in a reduced inflammatory response. Inactivation of FoxO1 subsequent to TLR4-dependent Akt activation has been reported previously to limit the overactivation of the innate immune response [34] . Curiously, TSC1-deficient macrophages produce elevated pro-inflammatory cytokines in response to multiple TLR stimuli [35] . As the activity of Akt was strongly reduced in these cells, it might be possible that some of these effects were actually mediated via mTORC2. Interestingly, a positive regulatory role of the TSC1-TSC2 complex for mTORC2 activation has been proposed [36] . In general, many studies in myeloid immune cells have been performed with pharmaceutical inhibitors of the mTOR pathway, as these cells are notoriously difficult to transfect. Since rapamycin inhibits mTORC2 in some cell types, it is possible that some of the rapamycin effects are actually due to inhibition of mTORC2 signalling. Further studies with tissue-specific knockout mice will be required to unwire the role of mTORC1 compared with mTORC2 in the innate immune system.
Inflammatory events in patients under mTOR inhibitor therapy
The general pro-inflammatory effects of mTORC1 inhibition in experimental models are supported by the immunological analysis of kidney transplant patients on rapamycin therapy. These patients display an increased inflammatory and immunostimulatory potential of myeloid DCs ex vivo compared with controls [13, 21] . These data were supported by an unbiased transcriptional analysis of rapamycin-treated kidney transplant recipients [37] . Hence the most prominent transcriptional alterations affected the innate immune cell system and NF-κB-mediated proinflammatory pathways [37] . The pro-inflammatory and immunostimulatory properties of rapamycin on myeloid immune cells in kidney transplant patients can be observed even in the presence of steroids, one of the strongest antiinflammatory agents used in clinical medicine [21] . The use of rapamycin in kidney transplantation is challenging due to the frequent occurrence of various side effects including inflammatory manifestations such as pneumonitis, glomerulonephritis or chronic inflammatory anaemia [38] . In a prospective observational study that analysed these inflammatory complications, 66 % of the patients displayed at least one inflammatory symptom [39] . After switching the patients to rapamycin, there was an increase in IL-6 and TNFα expression in the peripheral blood without the usual compensation of negative-feedback loops depending on IL-10 and soluble TNF receptors [39] . IL-6 and TNFα changes correlated with the intensity of the clinical inflammatory manifestations, suggesting that mTOR inhibition triggers a destabilization of the inflammatory cytokine balance in transplanted patients [39] . Proteinuria, which is another frequently observed side effect in patients treated with mTOR inhibitors, seems to originate from the activation of the innate immune system [40] . In contrast, kidney transplant patients on rapamycin rarely experience cytomegalovirus infection and reactivation, which is normally a serious problem in this patient cohort. The virus sustains mTORC1 activity during late phases of the viral cycle to promote viral protein expression and replication in macrophages and fibroblasts [41, 42] .
Upstream regulators of mTOR in innate immune cells
As elucidated above, PI3K is a major activator of mTORC1 and it plays a prominent role in transducing the TLR activating signal to mTORC1. Hence, similarly to mTORC1 inhibition, genetic disruption or pharmacological inhibition of PI3K augments IL-12 production in isolated murine splenic DCs [19] . Pharmacological inhibition of PI3K in a murine caecal ligation and puncture-induced polymicrobial sepsis model increases mortality caused by an amplified production of pro-inflammatory cytokines, including IL-1β, IL-6, IL-12 and TNFα, supporting the PI3K pathway to be a negative-feedback regulator for inflammatory cytokines [43] . Furthermore, stimulation of human monocytes with Porphyromonas gingivalis LPS during suppression of PI3K activity increases IL-12, but suppresses IL-10, synthesis [44] . Therefore it is possible to integrate the TSC/mTOR pathway downstream of PI3K in monocytes, macrophages and DCs for the regulation of inflammatory responses [10] (Figure 2) .
Recently, it was shown that the MAPK (mitogenactivated protein kinase) p38α activates the mTOR pathway in TLR-stimulated monocytes and macrophages [45] .
Mechanistically, p38α phosphorylates the p38 substrate MK2 (MAPK-activated protein kinase 2), which then phosphorylates and inactivates TSC2 to promote mTORC1 activation [45] . p38α-mediated mTORC1 activation is independent of PI3K, and the data suggest that p38α and PI3K concurrently modulate mTORC1 to balance IL-12 and IL-10 expression [45] (Figure 2) .
Another upstream regulator of mTORC1 constitutes Cot (cancer Osaka thyroid oncogene)/tpl2 (tumour progression locus 2), a kinase that is responsible for the activation of the MKK1 (MAPK kinase 1)/ERK1/2 (extracellularsignal-regulated kinase 1/2) pathway after activation of TLRs. Deficiency of Cot/tpl2 in LPS-stimulated peritoneal or bone-marrow-derived macrophages strongly reduces the activation of mTORC1 and increases the expression of IL-12p40 and of iNOS (inducible nitric oxide synthase) [46] . Moreover, Cot/tpl2 controls mRNA translation in TLR-activated macrophages through the mTORC1 pathway [47] . The dissociation of the 4E-BP-eIF4E (eukaryotic initiation factor 4E) complex, a key event in cap-dependent mRNA translation initiation, is dependent on Cot/tpl2 and increases cap-dependent translation of TNFα and IL-6 [47] . Translational control of IRF7 via the mTORC1/4E-BP1/2 pathway is also important to regulate the expression of type I IFNs [48] . Leishmania parasites cleave mTOR by a protease to inhibit host translation as a survival mechanism to promote Leishmania proliferation [49] .
Inhibition of mTOR in myeloid cells as therapeutic principle against cancer
Vaccination strategies involving DCs to induce potent tumour-specific T-cell responses that reduce the tumour mass and control tumour relapses are actively pursued. Inhibition of mTOR in TLR-stimulated DCs promotes the expression of the co-stimulatory molecule CD86, whereas PD-L1 (programmed cell death ligand 1), a negative regulator for Tcell activation, is decreased [10,13,27] (Figure 2) . Moreover, rapamycin augments autophagy, which is important for the presentation of endogenous and exogenous proteins on MHC class I and class II molecules, thereby promoting activation of CD8 + and CD4 + T-cells respectively [50] . Short-term inhibition of mTOR in monocytes or DCs during TLR stimulation augments the differentiation of pro-inflammatory anti-tumour CD4 + Th1 (T helper 1) cells in vitro [10, 20, 21] . Mice immunized with rapamycintreated DCs and the tuberculosis vaccine strain BCG (Bacille Calmette-Guérin) show enhanced Th1-mediated protection against virulent Mycobacterium tuberculosis [50] .
These T-cell promoting effects of mTOR inhibition in DCs have been exploited in various murine cancer models. Therapeutic autologous vaccination using DCs treated with TLR agonists plus rapamycin results in improved generation of CD8 + T-cells in vivo and improved antitumour immunity in a murine melanoma model [51] . Treatment of mice with an immunostimulatory agonistic anti-CD40 antibody together with AZD8055, an ATPcompetitive mTOR inhibitor, elicits synergistic anti-tumour responses in a metastatic renal cell carcinoma model [23] . Double-treated mice have a higher number of matured macrophages and DCs producing the anti-tumour cytokines IL-12, IFNγ and TNFα [23] . Interestingly, the effects were only observed with AZD8055, but not with rapamycin [23] . The mTOR pathway may be also critical for reprogramming monocytes/macrophages in the tumour microenvironment into TAMs (tumour-associated macrophages) that support tumour growth and progression by augmenting tumour angiogenesis [24] . mTORC1 activation by TSC2 knockdown causes monocytes to differentiate into efficient TAMs, releasing less IL-12 and more IL-10 and to adopt proangiogenic properties in vitro. Tumour angiogenesis and growth of murine xenografts is promoted by infusion of mice with TSC2-deficient monocytes. Macrophage depletion is sufficient to block the anti-angiogenic effects of rapamycin on tumours [24] .
Concluding remarks
In the last few years, an important role of the mTOR pathway for macrophage and DC biology has been elucidated. These results are underscored by the evaluation of the immune system of organ transplant patients receiving an mTOR inhibitor. Future studies with tissue-specific knockout mice that target individual components of the mTOR pathway proteins will decipher the exact role of mTORC1 and mTORC2 in macrophages as well as in DCs for immune responses and tissue homoeostasis. 
